PT-141 (Bremelanotide): How the Sexual Health Peptide Works

Key Takeaways

• Compounds covered: PT-141 (bremelanotide/Vyleesi), melanotan II (MT-II, for comparison/distinction only)
• Goal area: Sexual health — hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved indication).
• Evidence range: Phase III RCTs for female HSDD (RECONNECT program, N=1,267 across both trials); MT-II has no clinical trial data supporting human use.
• Regulatory range: Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women (2019); MT-II is not approved for human use. Superpower facilitates access to the FDA-approved product Vyleesi for its approved indication through licensed providers and does not offer or facilitate compounded bremelanotide.
• Key biomarkers: FSH, estradiol, total testosterone, free testosterone, LH, prolactin, blood pressure baseline, comprehensive metabolic panel
• As of April 2026: Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Its use for erectile dysfunction or male HSDD is off-label and not FDA-approved. Superpower does not facilitate bremelanotide access for off-label uses.
• Bottom line: Phase III RCT evidence supports bremelanotide for female HSDD, subject to ongoing debate about effect size and clinical significance; MT-II is not an appropriate substitute and carries documented dermatologic risks that PT-141 does not.

Understanding Sexual Desire Disorder: The Biology

Hypoactive sexual desire disorder is a disorder of the brain, not the genitals. Unlike conditions of arousal or orgasmic function, HSDD originates in the central neurocircuitry that generates sexual motivation and desire. The hypothalamus, limbic system, mesolimbic dopaminergic pathways, and cortical regions involved in reward processing are all implicated in the generation of sexual desire. This is why treatments that act exclusively on peripheral vasculature — as PDE5 inhibitors do — are not mechanistically suited to address desire deficits.

The melanocortin system is a key node in this central sexual arousal network. Pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus produce alpha-melanocyte stimulating hormone (alpha-MSH), which activates melanocortin receptor subtypes 3 and 4 (MC3R and MC4R). These receptors are expressed throughout the hypothalamus, amygdala, brainstem, and spinal cord — regions that coordinate sexual motivation, arousal signaling, and the neural drive to erection or lubrication. Pfaus and colleagues, in a 2022 CNS Spectrums review, provided a detailed account of the central melanocortin pathway's role in HSDD, including POMC, alpha-MSH, and the MC3R/MC4R receptor targets that bremelanotide engages.

A secondary mechanism involves the oxytocinergic system: Semple and colleagues demonstrated in a 2019 Molecular Neurobiology study that oxytocin neurons enable melanocortin regulation of male sexual function, linking the melanocortin system to the broader social bonding and affiliative neurobiology of sexual function. Modi and colleagues, in a 2015 Neuropsychopharmacology study, showed that melanocortin receptor agonists facilitate partner preference formation via oxytocin pathways, consistent with the desire rather than mere arousal component of PT-141's effect.

Peptides that engage this central melanocortin-oxytocin network are proposed to act on the neurobiological circuitry of sexual desire rather than on peripheral arousal mechanisms. This is the mechanistic rationale for why bremelanotide, acting centrally, is studied in HSDD rather than in conditions of peripheral arousal.

PT-141 vs. Melanotan II: A Quick Comparison

The search term "MT2 peptide" frequently appears alongside PT-141 in online research. These are distinct compounds. The following comparison is presented to clarify their differences; MT-II is not an appropriate substitute for PT-141 and is discussed for educational context only.

• Compound: PT-141 (bremelanotide/Vyleesi)
  Mechanism: Selective MC3R/MC4R agonism in CNS; proposed to engage sexual desire and arousal circuitry
  Evidence: Phase III RCT (RECONNECT dual-RCT, N=1,267 for female HSDD)
  FDA status: FDA-approved as Vyleesi for HSDD in premenopausal women (2019)
  SP availability: The FDA-approved product Vyleesi is available by prescription through conventional pharmacy channels when a licensed provider determines it is clinically appropriate for HSDD in premenopausal women. Superpower does not offer or facilitate compounded bremelanotide.
  Route: Subcutaneous injection (Vyleesi, FDA-approved).
• Compound: Melanotan II (MT-II)
  Mechanism: Broad melanocortin agonist — activates MC1R (pigmentation), MC3R, MC4R, MC5R; non-selective
  Evidence: No published clinical trials support human therapeutic use; safety and efficacy data are limited to case reports
  FDA status: Not FDA-approved for any indication; not on the § 503A Category 1 bulk drug substances list, not a component of an FDA-approved drug, and not covered by a USP or NF monograph, so it cannot be lawfully compounded and dispensed for human use under Section 503A
  SP availability: Not available through Superpower
  Route: Sold in unregulated gray-market injectable preparations

Products sold online as "research use only" are not a legal pathway to human administration (see FDA intended-use doctrine at 21 CFR § 201.128). MT-II's inclusion here is for educational context and safety distinction only.

PT-141 (Bremelanotide): Individual Profile

The evidence base for bremelanotide is substantial relative to most peptide therapeutics. Its FDA approval is supported by a formal phase 3 randomized controlled trial program.

Bremelanotide (PT-141/Vyleesi)

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist, available as the FDA-approved subcutaneous injection Vyleesi for HSDD in premenopausal women. The FDA-approved product Vyleesi is available by prescription from a licensed provider for HSDD in premenopausal women.

For HSDD, bremelanotide acts on MC3R and MC4R in the hypothalamus, limbic system, and related CNS structures; it is proposed to modulate central signaling implicated in sexual desire. Full prescribing information for Vyleesi is available at DailyMed. Borland and colleagues, in a 2025 Neuropharmacology animal-model study, characterized bremelanotide's central pro-sexual actions via MC4R pathway mechanisms.

The RECONNECT phase 3 program comprised two double-blind, placebo-controlled randomized trials in premenopausal women with HSDD (N=1,267 combined across both trials). Kingsberg and colleagues, in the pivotal 2019 publication in Obstetrics and Gynecology, established bremelanotide's primary efficacy on satisfying sexual events and sexual distress scores. Simon and colleagues, in the 52-week long-term safety extension published in Obstetrics and Gynecology, confirmed sustained benefit without tolerance development and characterized the safety profile across a full year of treatment. Simon and colleagues, in a 2022 Journal of Women's Health prespecified subgroup analysis from RECONNECT, showed consistent efficacy across subgroups defined by age, BMI, and comorbidity, supporting generalizability of the response. [Phase III RCT]

The evidence base has also been subject to independent critical analysis. Spielmans and colleagues, in a 2024 Journal of Sex Research analysis, questioned the clinical significance of effect sizes in RECONNECT; an earlier 2021 analysis by the same group raised concerns about outcome reporting choices. Balanced coverage of a clinical trial program includes both the regulatory evidence base and the published critical literature. Patients and providers should review both when making decisions. Clayton and colleagues, in a 2022 Journal of Women's Health comprehensive safety review, assessed nausea (approximately 40%), flushing (approximately 20%), and transient blood pressure data across the full clinical development program. Koochaki and colleagues, in a 2021 patient-experience analysis from RECONNECT, reported meaningful improvements in sexual distress and partner impact outcomes.

Bremelanotide is FDA-approved as Vyleesi for premenopausal women with HSDD. For women who prefer not to use bremelanotide or for whom it is contraindicated, Parish and colleagues in a 2021 ISSWSH clinical practice guideline in the Journal of Sexual Medicine addressed systemic testosterone as an alternative approach for women with HSDD; Ribera Torres and colleagues in a 2024 Gynecological Endocrinology systematic review reviewed testosterone's evidence base for female sexual interest and arousal disorder. These represent distinct mechanisms and distinct patient populations. Vyleesi is available by prescription through conventional pharmacy channels from a licensed healthcare provider for HSDD in premenopausal women.

Melanotan II: Why It Is Not PT-141

This compound has not been approved by the FDA for any medical use. Research is limited to laboratory and early animal studies; clinical trial data supporting human therapeutic use do not exist. It is not prescribed, compounded, or dispensed through Superpower. Inclusion here is for educational context and safety distinction only.

MT-II's non-selective melanocortin agonism activates MC1R, which controls melanocyte proliferation and pigmentation — an effect that PT-141 does not meaningfully produce. The documented dermatologic risks include melanoma and atypical melanocytic nevi: Hjuler and colleagues in a 2014 Dermatology case report linked melanotan-II use to melanoma development; Reid and colleagues in a 2013 Irish Medical Journal case series documented atypical melanocytic nevi in melanotan injectors; Cardones and colleagues in a 2009 Archives of Dermatology report described alpha-MSH receptor activation producing eruptive nevi. These risks arise specifically from MC1R agonism at melanocytes. PT-141's targeted MC3R/MC4R selectivity — characterized by Molinoff and colleagues in a 2003 Annals of the New York Academy of Sciences paper describing PT-141 as a melanocortin agonist for sexual dysfunction — represents a fundamentally different safety profile. MT-II products sold online are unregulated, have no pharmaceutical-grade manufacturing standards, and are not subject to FDA oversight. [No clinical evidence for human therapeutic use]

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry the following regulatory statuses.

• Bremelanotide (PT-141/Vyleesi): FDA-approved in 2019 as Vyleesi for HSDD in premenopausal women. Because Vyleesi is commercially available and not on the FDA drug shortage list, 503A compounding of bremelanotide is permissible only where the prescriber documents a patient-specific clinical difference from Vyleesi per FDA's January 2018 essentially-copies guidance. Off-label prescribing of Vyleesi (or of any compounded bremelanotide prepared under the narrow clinical-difference exception) is a practice-of-medicine decision.
• Melanotan II (MT-II): An unapproved new drug. Not FDA-approved for any indication, not on the § 503A Category 1 bulk drug substances list, not a component of an FDA-approved drug, and not covered by a USP or NF monograph; it cannot be lawfully compounded and dispensed for human use under Section 503A. Products sold online as "research use only" are not a legal pathway to human administration (see FDA intended-use doctrine at 21 CFR § 201.128). Not prescribed or dispensed through Superpower.

How Bremelanotide Compares to Hormonal Options for HSDD

Bremelanotide is not the only evaluated pharmacological approach to HSDD. The comparison between bremelanotide and systemic testosterone for women is clinically relevant and worth addressing directly.

Bremelanotide's mechanism: Central CNS activation of MC3R/MC4R; acts on the brain's desire circuitry. Used on-demand (before anticipated sexual activity), not continuously.

Testosterone for female HSDD: Systemic testosterone is used off-label in women with HSDD, particularly postmenopausal women in whom testosterone deficiency is a contributing factor. Uloko and colleagues, in a 2022 International Journal of Impotence Research paper, clarified that testosterone's primary clinical application for HSDD is postmenopausal women, which is distinct from bremelanotide's premenopausal indication. Clayton and colleagues, in the Phase 2b dose-ranging study published in Women's Health in 2016, established bremelanotide's earlier-phase efficacy evidence predating the Phase 3 program. These are complementary rather than competing approaches for different HSDD patient profiles.

Direct cross-compound comparisons between bremelanotide and testosterone for HSDD are not available from randomized head-to-head trials. Any comparison is between compounds studied in different populations using different endpoints. Clinical decisions account for individual menopausal status, hormonal profile, and the nature of the desire deficit.

Considerations When Evaluating Bremelanotide

Evaluating whether bremelanotide is appropriate requires clinical assessment rather than self-selection. Several factors shape the clinical conversation.

Premenopausal vs. postmenopausal status: The FDA-approved indication is for premenopausal women. For postmenopausal women with HSDD, the clinical pathway typically involves hormonal evaluation first, as testosterone deficiency and estrogen withdrawal are primary contributors in that population. Any off-label use of Vyleesi is a practice-of-medicine decision made by a licensed prescriber.

Hormonal contributors to low desire: Elevated prolactin, testosterone deficiency, and thyroid dysfunction can all present as low sexual desire and are correctable through other means. A provider will evaluate these before bremelanotide is considered.

Cardiovascular and blood pressure profile: The transient blood pressure elevation associated with bremelanotide is clinically relevant for anyone with hypertension. Provider evaluation of baseline cardiovascular status is standard before prescribing.

Route and frequency: Bremelanotide is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times per month. This on-demand profile differs from continuous hormonal therapies and affects the clinical discussion around tolerability and adherence.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate full health history, current medications, and baseline lab results before recommending bremelanotide.

Safety Considerations

Bremelanotide's safety profile has been characterized across the full clinical development program, from Phase 2b through the 52-week long-term extension.

The most common adverse effects are nausea (~40%), flushing (~20%), injection-site bruising (~12%), and headache (~11%), from Vyleesi prescribing information. Transient blood pressure elevation (mean increase approximately 6 mmHg systolic, 4 mmHg diastolic) has been documented, returning to baseline within 12 hours in most individuals. Hyperpigmentation of the face, gums, and breasts has been reported with use beyond the recommended frequency.

Contraindications that apply broadly to bremelanotide include:

• Uncontrolled hypertension or known cardiovascular disease — bremelanotide's transient BP elevation requires cardiovascular safety evaluation
• Pregnancy — bremelanotide has not been studied in pregnant populations; animal data showed fetal risk
• Known hypersensitivity to bremelanotide or any formulation component
• History of hormone-sensitive cancer — where any melanocortin pathway activation requires oncology clearance

For a complete side effect and contraindication profile, see the individual compound page for PT-141/Vyleesi linked above.

What to Test Before Starting Bremelanotide

Regardless of whether bremelanotide is ultimately the appropriate option, baseline biomarker testing characterizes what is actually driving reduced sexual desire. Without it, there is no objective way to rule out correctable hormonal contributors — prolactin elevation, testosterone deficiency, thyroid dysfunction — before proceeding to a CNS-acting pharmacological option.

• FSH and estradiol: Establish premenopausal status (per the approved indication) and characterize the hormonal context. Elevated FSH and low estradiol suggest peri- or post-menopausal status, which affects the clinical pathway. Testing FSH and estradiol establishes this foundation.
• Total and free testosterone: Testosterone deficiency in women is associated with HSDD. Total testosterone and free testosterone provide the androgen picture relevant to sexual desire.
• Prolactin: Elevated prolactin is a reversible cause of low sexual desire and low testosterone. Prolactin should be assessed before initiating any therapy for reduced desire.
• TSH and thyroid function: Hypothyroidism and hyperthyroidism both affect libido. Thyroid function should be baseline-assessed before attributing desire deficits to HSDD specifically.
• Blood pressure: Given bremelanotide's transient BP effect, baseline blood pressure measurement is required before prescribing.
• Comprehensive metabolic panel: Liver and kidney safety baseline; relevant for any prescription therapy.

FSH, estradiol, total and free testosterone, prolactin, and thyroid function together establish the hormonal picture that precedes any bremelanotide discussion. Testing through a comprehensive hormonal baseline before a provider conversation provides the data that informs a clinical discussion about any appropriate intervention for reduced sexual desire — pharmacological or otherwise.

How to Access Bremelanotide Safely

The FDA-approved product Vyleesi is available by prescription from a licensed healthcare provider for HSDD in premenopausal women. Any use outside the FDA-approved indication is a decision made exclusively by a licensed prescriber exercising independent clinical judgment.

A provider evaluation for bremelanotide typically involves: a health history that includes sexual function assessment, baseline hormonal labs, blood pressure evaluation, and a review of current medications (particularly any vasodilatory agents). Providers who specialize in sexual health or women's health are the appropriate referral pathway.

Gray-market products sold as "PT-141" or "MT-II" through online peptide vendors are not equivalent to the FDA-approved product Vyleesi. They lack standardized manufacturing, sterility testing, and dosing verification. The risks associated with unregulated injectable products — contamination, dosing errors, microbial contamination — apply to any product outside the licensed pharmacy supply chain.

Understanding Your Baseline

Bremelanotide addresses a specific mechanism: central melanocortin receptor activation driving sexual desire. It does not address prolactin excess, testosterone deficiency, thyroid dysfunction, or relationship factors — all of which can present as reduced desire. Baseline testing establishes which of these mechanisms is operative in a given individual, making the provider conversation about bremelanotide a targeted clinical decision rather than an empirical trial.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to a pharmacological option, a hormonal evaluation, or a non-pharmacological approach, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Bremelanotide (PT-141/Vyleesi) is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Full prescribing information for the approved product is available in its FDA-approved labeling at dailymed.nlm.nih.gov. This article addresses only the FDA-approved indication for Vyleesi (HSDD in premenopausal women). Any off-label use is outside the scope of this article. Superpower Health facilitates access to the FDA-approved product Vyleesi through licensed healthcare providers for its FDA-approved indication. Superpower does not facilitate access to bremelanotide for off-label uses and does not prescribe or dispense medications.

Contraindications: Do not use if you have uncontrolled hypertension or known cardiovascular disease without clinical evaluation and provider approval. Bremelanotide is contraindicated in pregnancy (animal studies indicate fetal harm). Known hypersensitivity to bremelanotide or any formulation component is a contraindication.

Warnings: Transient blood pressure elevation (mean increase of approximately 6 mmHg systolic, 4 mmHg diastolic at peak) has been documented, returning to baseline within 12 hours in most individuals; monitor blood pressure before use in individuals with elevated baseline BP. Focal hyperpigmentation of the face, gums, and breasts has been reported with use beyond the recommended frequency (more than once in 24 hours or more than 8 times per month). Do not use with organic nitrates, guanylate cyclase stimulators, or other vasodilatory medications without provider guidance.

Common side effects: Nausea (40%), flushing (20%), injection-site bruising (12%), headache (11%). Nausea is the most common reason for discontinuation.

As of April 2026, bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Its use for erectile dysfunction or male HSDD is off-label and not FDA-approved. Superpower does not facilitate bremelanotide access for off-label uses.

Melanotan II (MT-II): Melanotan II is not approved by the FDA for any medical use. Research on this compound has not established human safety or efficacy. Its non-selective melanocortin agonism has been associated in case reports with melanoma development and atypical melanocytic nevi. MT-II is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes and safety distinction only. MT-II is not an appropriate substitute for bremelanotide.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.